Navigation Links
Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
Date:8/25/2008

Industry Leader in Generic Market Information Offers Single Authoritative Source of API Sourcing and Global Regulatory Intelligence to Indonesia's

Generics and API Manufacturers

JAKARTA, Indonesia, Aug. 26 /Xinhua-PRNewswire/ -- Indonesia's generics and API (Active Pharmaceutical Ingredient) manufacturers get boost in competitive advantage from launch of two solutions in the market by the Scientific business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals. Newport Horizon Premium(TM) is designed specifically for professionals working in product selection, business development, competitive intelligence and API (Active Pharmaceutical Ingredient) sourcing. IDRAC(R) is a single comprehensive source of global regulatory intelligence. Their use by generic and OTC (Over the Counter) pharmaceutical companies and API manufacturers in Indonesia will enable them to develop products more quickly, keep up with changing global regulatory requirements and speed product registration and commercialisation, thereby expanding their business footprint in Asia and beyond.

The two solutions can help provide a competitive boost to Indonesia's pharmaceutical industry which is forecast to reach US$3.75bn in value by 2012 according to Business Monitor International in April 2008.

Said Mr. Wong Woei Fuh, Commercial Director Asia Pacific, Scientific business of Thomson Reuters, "To stay competitive in the generics market, pharmaceutical companies and API manufacturers in Indonesia have a critical need for authoritative market information as well as time and money-saving API sourcing solutions. Customers will benefit from our one-stop global resource of intelligence which will help them improve productivity, accelerate time to market and gain that competitive edge to expand their footprint globally, part of the government's drive to promote the local pharmaceuticals industry. As the industry authority on the global generics market, we believe Newport Horizon Premium and IDRAC are well-placed to help Indonesia's pharmaceutical industry expand its capability."

Newport Horizon Premium (NHP) combines sales, consumption, launch, patent, patent challenge, exclusivity, chemistry, prescribing and regulatory information for more than 10,000 molecules, 18,000 companies, 68 markets and 92 patent countries worldwide with unique, early API development and manufacturing intelligence. They build on the substantial success of Horizon Global, by adding patented and published routes of synthesis on thousands of molecules, with listed intermediates and reagents, sourced from Prous Science's respected Synthline database. Newport Horizon Premium also has kilogram and IU (International Units) API consumption data from IMS Health added to the data and capabilities already available. This data is now available for thousands of drugs by region and by dose form for both the current and previous year and allow customers to evaluate scale, consumption trends and prices for active ingredients, all of which can be difficult to estimate using sales data alone.

NHP addresses the needs of large and small players in the pharmaceuticals market and features powerful multi-criteria search functionalities. It is aimed at helping generic, OTC and API companies in their constant struggle to build deals faster and accelerate time to market.

IDRAC is a single authoritative source of global regulatory intelligence for drug development, registration and commercialisation in almost 60 countries and regions, replacing the time-consuming tasks of acquiring, compiling and analyzing this information. With IDRAC, pharmaceutical companies can plan clinical trials better, accelerate product registration and commercialization and optimise market penetration. NHP and IDRAC are available in Indonesia through Scientific's representative in Indonesia, PT Piranti.

The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Our authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success. Scientific information solutions can be found at scientific.thomsonreuters.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.

Contact:

Pamela Lim

Manager, PR & Communications

Scientific

Tel: +65-6411-6737

Email: Pamela.lim@thomsonreuters.com


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the ... users and those who do not use the app. Dr. Mohebi, the founder of Parsa ... Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat ...
(Date:5/26/2016)... ... 26, 2016 , ... Eating Recovery Center, Washington ... a brand new child and adolescent residential treatment center on June 1. The ... more specialized eating disorder treatment and access to life-saving care. , To celebrate, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
Breaking Medicine Technology: